Catharina M. Korse

Catharina M. Korse

Auto-generated profile, based on publicly available information

Catharina M. Korse

Department of Clinical Chemistry, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, PO Box 90203, 1006 BE Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in European Journal of Cancer
Verified
Journal Article
Closed access
CKCatharina M. Korse
Catharina M. Korse
BTBabs G. Taal
Babs G. Taal
MVMarie-Louise van Velthuysen
Marie-Louise van Velthuysen
OVOtto Visser
Otto Visser

10 September 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CKCatharina M. Korse
Catharina M. Korse
BTBabs G. Taal
Babs G. Taal
CGCornelis A. de Groot
Cornelis A. de Groot
RBRobert H. Bakker
Robert H. Bakker
JBJohannes M.G. Bonfrer
Johannes M.G. Bonfrer
Purpose: For the last decade chromogranin-A (CgA) has been a well-established marker for neuroendocrine tumor (NET), and N-terminal pro-brain natriuretic peptide (NT-proBNP) has been a useful marker for left ventricular dysfunction. This study examined the diagnostic value of CgA and NT-proBNP for carcinoid heart disease (CHD), and their prognostic value for overall survival in NET patients. Patients and Methods: Serum samples were obtained and cardiac ultrasound studies performed in 102 NET patients. The criterion for mild and severe CHD was tricuspid regurgitation stage I/II and III/IV, respectively. Proportional odds and Cox proportional hazards models were constructed respectively to identify the association between CHD and overall survival with patient characteristics and the two markers. Results: Severe CHD was found in 15 (15%) of 102 patients, 13 of whom had elevated NT-proBNP levels. In the univariate proportional odds model CHD was correlated with age (P = .007), CgA (P = .002), and NT-proBNP (P < .001), whereas in the multivariate model NT-proBNP and CgA were significantly associated with CHD (P < .001 and P = .01). In the univariate Cox models, age (P = .04), sex (P = .03), CgA (P = .003), and NT-proBNP (P = .04) were related to overall survival, and in the multivariate model CgA and NT-proBNP remained significantly related to overall survival (P = .002 and P = .04, respectively). Conclusion: NT-proBNP and CgA are very important markers in the diagnosis of CHD in patients with NET. Furthermore, patients with elevated NT-proBNP in addition to elevated CgA levels showed worse overall survival than patients with elevated CgA alone.

1 March 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
CKCatharina M. Korse
Catharina M. Korse
BTBabs G. Taal
Babs G. Taal
AVAndrew Vincent
Andrew Vincent
MVMarie-Louise van Velthuysen
Marie-Louise van Velthuysen
PBPaul Baas
Paul Baas
JBJohannes M.G. Bonfrer
Johannes M.G. Bonfrer

27 May 2009 in BMC Neurology
Verified
Journal Article
Open access
PDF file
BMBarbara C van Munster
Barbara C van Munster
CKCatharina M Korse
Catharina M Korse
SRSophia E de Rooij
Sophia E de Rooij
JBJohannes M Bonfrer
Johannes M Bonfrer
AZAeilko H Zwinderman
Aeilko H Zwinderman
JKJohanna C Korevaar
Johanna C Korevaar
S100B protein and Neuron Specific Enolase (NSE) can increase due to brain cell damage and/or increased permeability of the blood-brain-barrier. Elevation of these proteins has been shown after various neurological diseases with cognitive dysfunction. Delirium is characterized by temporal cognitive deficits and is an important risk factor for dementia. The aim of this study was to compare the level of S100B and NSE of patients before, during and after delirium with patients without delirium and investigate the possible associations with different subtypes of delirium.

7 October 2008 in Neuroendocrinology
Verified
Journal Article
Closed access
CKCatharina M. Korse
Catharina M. Korse
JBJohannes M.G. Bonfrer
Johannes M.G. Bonfrer
NANeil K. Aaronson
Neil K. Aaronson
AHAugustinus A.M. Hart
Augustinus A.M. Hart
BTBabs G. Taal
Babs G. Taal
Background: Urinary 5-HIAA excretion is a well-known marker in neuroendocrine tumors (NETs), but it has a low sensitivity and the 24-hour collection is inconvenient for patients. Chromogranin A (CgA) is a promising marker, but a thorough evaluation during follow-up is still lacking. Methods: 39 patients with metastatic gastrointestinal NETs were monitored during treatment with the long-acting octreotide SandostatinLAR®. A comparison was made between serum CgA and urinary 5-HIAA in relation to quality of life (HRQL) assessed by the EORTC QLQ-C30 questionnaire, supplemented with questions specific to carcinoid symptoms. Survival analyses were performed to examine the association between the markers and survival time. Results: Correlations were found between CgA and physical functioning (p = 0.01) and quality of life (p = 0.03), while no significant correlations were observed between 5-HIAA levels and any of the self-reported health outcomes. Cox regression showed an association between CgA levels and survival time (p = 0.02), while no significant association was observed between 5-HIAA levels and survival time. Conclusion: Stronger correlations of CgA compared to 5-HIAA with physical functioning and wellbeing, the convenience of measuring in blood, as well as the prognostic value of CgA for survival, makes CgA the recommended marker in the management of patients with metastatic NETs.

1 January 2015 in Clinica Chimica Acta
Verified
Journal Article
Open access
CKCatharina M. Korse
Catharina M. Korse
Stefan HoldenriederStefan Holdenrieder
Stefan Holdenrieder
XZXiu-Yi Zhi
Xiu-Yi Zhi
XZXiaotong Zhang
Xiaotong Zhang
LQLing Qiu
Ling Qiu
RMRafael Molina
Rafael Molina
We performed a multicenter evaluation of the Elecsys® progastrin-releasing peptide (ProGRP) immunoassay in Europe and China. The assay was evaluated at three European and two Chinese sites by imprecision, stability, method comparison and differentiation potential in lung cancer. Intermediate imprecision across five analyte concentrations ranged from 2.2% to 6.0% coefficient of variation. Good stability for plasma and serum samples was shown for various storage conditions. There was excellent correlation between the Elecsys® and ARCHITECT assays in plasma (slope 1.02, intercept -2.72pg/mL). The Elecsys® assay also showed good correlation between serum and plasma samples (slope 0.93, intercept 2.35pg/mL; correlation coefficient 0.97). ProGRP differentiated small-cell and non-small-cell lung cancer (NSCLC; area under the curve 0.90, 95% CI 0.87-0.93; 78.3% sensitivity, 95% specificity; at 84pg/mL), with no relevant effects of ethnicity, age, gender or smoking. Median ProGRP concentrations were low in benign diseases (38pg/mL), other malignancies (40pg/mL) or NSCLC (39pg/mL), except chronic kidney disease above stage 3 (>100pg/mL). Increased stability of the Elecsys® ProGRP assay in serum and plasma offers clear benefits over existing assays. This first evaluation of a ProGRP assay in China demonstrated comparable differentiation potential among different ethnicities.